APYX trades 121.8% below Wall Street's consensus target of $6.50.
Last 12 months price action with 12-month analyst target path
The base valuation assumes APYX achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 9 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of November 8, 2026, Apyx Medical Corporation (APYX) has a Wall Street consensus price target of $6.50, based on estimates from 9 covering analysts. With the stock currently trading at $2.93, this represents a potential upside of +121.8%. The company has a market capitalization of $123M.
Analyst price targets range from a low of $6.00 to a high of $7.00, representing a 15% spread in expectations. The median target of $6.50 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 8 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, APYX trades at a trailing P/E of -15.5x. Analysts expect EPS to grow -29.4% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 SSKNSTRATA Skin Sciences, Inc. | $589 | $0.00 | — | — | — | — | — |
 ARAYAccuray Incorporated | $13M | $0.11 | — | — | — | — | — |
 INVAInnoviva, Inc. | $1.4B | $19.10 | $38.00 | +99.0% | Buy | 7.9x | 11 |
 AEYEAudioEye, Inc. | $155M | $12.37 | $21.00 | +69.8% | Buy | 11.9x | 7 |
 INMDInMode Ltd. | $766M | $13.33 | $19.00 | +42.5% | Hold | 10.3x | 11 |
 LNTHLantheus Holdings, Inc. | $6.6B | $100.61 | $102.65 | +2.0% | Buy | 18.8x | 19 |
 MDTMedtronic plc | $130.7B | $101.80 | $97.73 | -4.0% | Buy | 17.0x | 51 |
 SYKStryker Corporation | $124.9B | $325.87 | $354.47 | +8.8% | Buy | 22.0x | 52 |
 BSXBoston Scientific Corporation | $63.5B | $42.75 | $54.65 | +27.8% | Buy | 13.5x | 44 |
 ABTAbbott Laboratories | $191.5B | $109.93 | $121.36 | +10.4% | Buy | 19.9x | 43 |
Quick answers to the most common questions about buying APYX stock.
The consensus Wall Street price target for APYX is $6.5, representing 121.8% upside from the current price of $2.93. With 9 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
APYX has a consensus rating of "Buy" based on 9 Wall Street analysts. The rating breakdown is predominantly bullish, with 8 Buy/Strong Buy ratings. The consensus 12-month price target of $6.5 implies 121.8% upside from current levels.
APYX's current price is $2.93 with a consensus target of $6.5 (121.8% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $7 for APYX, while the most conservative target is $6. The consensus of $6.5 represents the median expectation. These targets typically reflect 12-month expectations.
APYX is moderately covered, with 9 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 8 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month APYX stock forecast based on 9 Wall Street analysts shows a consensus price target of $6.5, with estimates ranging from $6 (bear case) to $7 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on APYX, with a "Buy" consensus rating and $6.5 price target (121.8% upside). 8 of 9 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
APYX analyst price targets range from $6 to $7, a 15% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $6.5 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.